Count on a familiar pMDI for patients already using beclometasone/formoterol formulations1,5-7
Bibecfo offers similarity to the originator, Fostair (beclometasone/formoterol), in multiple ways1,5-7
| Beclometasone/formoterol combination |
Bibecfo from Cipla | Fostair from Chiesi |
|---|---|---|
| Available strengths | 100/6mcg, 200/6mcg | 100/6mcg, 200/6mcg |
| Excipients* | Norflurane, (HFA-134a), ethanol anhydrous, hydrochloric acid | Norflurane, (HFA-134a), ethanol anhydrous, hydrochloric acid |
| Dose counter | YES | YES |
| Same, step-by-step instructions** | YES | YES |
| Indicated for MART | 100/6mcg | 100/6mcg |
| Indicated for asthma maintenance | 100/6mcg and 200/6mcg | 100/6mcg and 200/6mcg |
| Indicated for regular treatment of COPD | 100/6mcg | 100/6mcg |
| Extrafine formulation | YES | YES |
*The safety of a medicinal product can also be compromised by the intrinsic toxicity of the excipients themselves.
Bibecfo contains hydrochloric acid as a pH-buffering agent10,11
**All patients must be reviewed when transitioning from one treatment to another.
At less than half the price of Fostair, Bibecfo could help make your budgets go further to optimise more patients’ care1,5-7
NHS list price of 120 dose presentations of extrafine beclometasone and formoterol in 100/6mcg and 200/6mcg strength2
| Pack strength | Bibecfo | Fostair |
|---|---|---|
| 100/6mcg | £13.98 | £29.32 |
| 200/6mcg | £13.98 | £29.32 |
Costs documented June 2025 from the Dictionary of Medicines and Devices (dm+d).2
Fostair is a registered trademark of Chiesi Ltd
COPD = chronic obstructive pulmonary disease; FEV1 = forced expiratory volume;
MART = maintenance and reliever therapy; MDI = pressurised metered dose inhaler.
Bibecfo indications1
Bibecfo 100/6mcg and 200/6mcg are indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting β₂-agonist) is appropriate:
- patients not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled rapid-acting β₂-agonist
or
- patients already adequately controlled on both inhaled corticosteroids and long-acting β₂-agonists
Bibecfo 100/6mcg is indicated in the symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.
Bibecfo 100/6mcg and 200/6mcg are indicated in adults 18 years and above. For Bibecfo 100/6mcg in asthma, no recommendation on a dose can be made in children and adolescents 17 years and under.
